Pacira BioSciences, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of non-opioid pain management and inflammation therapies. Headquartered in Parsippany, New Jersey, USA, the company's primary focus is on improving the lives of patients by providing innovative solutions that address unmet needs in pain management.
Core Business and Products:
Continue…Pacira's flagship product is EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local anesthetic. EXPAREL is used for postsurgical analgesia (pain relief after surgery) and is administered as a single injection at the surgical site. Its extended duration of action aims to reduce the need for systemic opioids, contributing to decreased opioid-related side effects and potential for abuse. The company actively promotes EXPAREL through a robust sales force that targets surgeons and anesthesiologists across various surgical specialties.
Beyond EXPAREL, Pacira's pipeline includes other projects focused on pain management and inflammation. The company explores different approaches and drug delivery systems to address unmet needs in this therapeutic area. Their research and development efforts aim to expand their portfolio of non-opioid pain management options.
Business Model:
Pacira's business model centers on the successful commercialization of its products, primarily EXPAREL. Revenue is generated through direct sales to hospitals, ambulatory surgery centers (ASCs), and other healthcare facilities. The company maintains a dedicated sales team responsible for promoting its products and building relationships with key healthcare professionals. A key aspect of their strategy is highlighting the clinical and economic benefits of EXPAREL, including reduced opioid use and associated costs.
Market Position and Competition:
Pacira competes in a market characterized by a growing need for effective and safer alternatives to opioid-based pain management. They are a key player in the evolving landscape of non-opioid pain management solutions. Their competitive advantage lies in EXPAREL's unique long-acting delivery system and established clinical profile. The company faces competition from other local anesthetics and pain management therapies, including both established products and emerging innovative treatments.
Financial Performance: (Note: Specific financial details are not included here as the prompt requested information directly from the provided website without financial data analysis.)
Overall:
Pacira BioSciences is a leading company focused on non-opioid pain management. Their success hinges on the continued market adoption of EXPAREL and the successful development and launch of future products in their pipeline. The company's dedication to innovation and commitment to reducing opioid reliance positions it well within a rapidly evolving healthcare landscape.
